ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type

Control of Heterologous Simian Immunodeficiency Virus SIVsmE660 Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques

(2018) Shakti Singh et al.   JOURNAL OF VIROLOGY

Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant

(2018) Yingxia Wen et al.   PLoS One

Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection

(2018) Sarah Auclair et al.   PLoS Pathogens

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial

(2018) Linda-Gail Bekker et al.   Lancet HIV

Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV

(2018) Margaret E. Ackerman et al.   NATURE MEDICINE

Priming and Activation of Inflammasome by Canarypox Virus Vector ALVAC via the cGAS/IFI16–STING–Type I IFN Pathway and AIM2 Sensor

(2017) Fengliang Liu et al.   JOURNAL OF IMMUNOLOGY

Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251Acquisition

(2016) Shari N. Gordon et al.   JOURNAL OF IMMUNOLOGY

Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

(2016) Monica Vaccari et al.   NATURE MEDICINE

Sustained virologic control in SIV+ macaques after antiretroviral and  4 7 antibody therapy

(2016) S. N. Byrareddy et al.   SCIENCE

Trained immunity: A program of innate immune memory in health and disease

(2016) M. G. Netea et al.   SCIENCE

Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates

(2015) Xiaoying Shen et al.   JOURNAL OF VIROLOGY

Mucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal Challenge

(2015) Iskra Tuero et al.   PLoS Pathogens

Immune Focusing and Enhanced Neutralization Induced by HIV-1 gp140 Chemical Cross-Linking

(2013) T. Schiffner et al.   JOURNAL OF VIROLOGY

The Canarypox Virus Vector ALVAC Induces Distinct Cytokine Responses Compared to the Vaccinia Virus-Based Vectors MVA and NYVAC in Rhesus Monkeys

(2013) J. E. Teigler et al.   JOURNAL OF VIROLOGY

Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine

(2013) Scott M. Hammer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial

(2013) Raphael Gottardo et al.   PLoS One

Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG

(2013) G. D. Tomaras et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antibodies with High Avidity to the gp120 Envelope Protein in Protection from Simian Immunodeficiency Virus SIVmac251Acquisition in an Immunization Regimen That Mimics the RV-144 Thai Trial

(2012) Poonam Pegu et al.   JOURNAL OF VIROLOGY

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144

(2012) Merlin L Robb et al.   LANCET INFECTIOUS DISEASES

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

(2012) Morgane Rolland et al.   NATURE

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

(2012) Barton F. Haynes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Global trends in molecular epidemiology of HIV-1 during 2000–2007

(2011) Joris Hemelaar et al.   AIDS

Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study

(2011) Glenda E Gray et al.   LANCET INFECTIOUS DISEASES

Updated aluminum pharmacokinetics following infant exposures through diet and vaccination

(2011) Robert J. Mitkus et al.   VACCINE

R5 Clade C SHIV Strains with Tier 1 or 2 Neutralization Sensitivity: Tools to Dissect Env Evolution and to Develop AIDS Vaccines in Primate Models

(2010) Nagadenahalli B. Siddappa et al.   PLoS One

Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

(2009) Supachai Rerks-Ngarm et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

(2008) Susan P Buchbinder et al.   LANCET

Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants

(2008) Stephanie C. Eisenbarth et al.   NATURE